Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

UDP-glucuronosyltransferase

Williams JA, Hyland R, Jones BC, Smith DA, Hurst S, Goosen TC, et al. Drug-drug interactions for UDP-glucuronosyltransferase substrates a pharmacoki-... [Pg.458]

Smith PA, Sorich M, McKinnon R, Miners JO. QSAR and pharmacophore modelling approaches for the prediction of UDP-glucuronosyltransferase substrate selectivity and binding. Pharmacologist 2002 44 supplement. [Pg.462]

Smith PA, Sorich MJ, McKinnon RA, Miners JO. Pharmacophore and quantitative structure-activity relationship modeling complementary approaches for the rationalization and prediction of UDP-glucuronosyltransferase 1A4 substrate selectivity. J Med Chem 2003 46 1617-26. [Pg.462]

Sorich MJ, Miners JO, McKinnon RA, Smith PA. Multiple pharmacophores for the investigation of human UDP-glucuronosyltransferase isoform substrate selectivity. Mol Pharmacol 2004 65 301-8. [Pg.462]

Sorich MJ, McKinnon RA, Miners JO, Winkler DA, Smith PA. Rapid prediction of chemical metabolism by human UDP-glucuronosyltransferase isoforms using quantum chemical descriptors derived with the electronegativity equalization method. J Med Chem 2004 47 5311-7. [Pg.462]

Similar to 5-FU, there is a polymorphism associated with irinotecan toxicity. UDP-glucuronosyltransferase (UGT1A1) is an enzyme responsible for the glucuronidation of SN-38 to inactive metabolites, and reduced or deficient levels of this enzyme correlate with irinotecan-induced diarrhea and neutropenia.39 Recently the FDA approved a blood test that detects variations in this gene. This test will assist health care providers in predicting which patients may develop severe toxicities from normal doses of irinotecan and can be ordered prior to patients receiving irinotecan. binotecan is administered as an IV bolus over 60 to 90 minutes in a variety dosing schedules. [Pg.1351]

Linnet, K. (2002). Glucuronidation of olanzapine by cDNA-expressed human UDP-glucuronosyltransferases and human liver microsomes. Hum. Psychopharmacol, 17, 233-8. [Pg.58]

Mori, A. etal. (2005).UDP-glucuronosyltransferase lA4polymorphismsinaJapanesepopulation and kinetics of clozapine glucuronidation. Drug Metab. Dispos., 33, 672-5. [Pg.59]

Fisher, M.B., Paine, M.F., Strelevitz, T.J. and Wrighton, S.A. (2001) The role of hepatic and extrahepatic UDP-glucuronosyltransferases in human drug metabolism. Drug Metabolism Reviews, 33, 273-297. [Pg.223]

Basu, N.K., Ciotti, M., Hwang, M.S. et al. (2004) Differential and special properties of the major human UGT1-encoded gastrointestinal UDP-glucuronosyltransferases enhance potential to control chemical uptake. The Journal of Biological Chemistry, 279, 1429-1441. [Pg.223]

UDP-glucuronosyltransferase gene and irinotecan toxicity a pharmaco-genetic analysis, Cancer Res. 2000, 60, 6921-6926. [Pg.310]

Lampe JW, Bigler J, Horner NK et al. UDP-glucuronosyltransferase (UGT1A1 28 and UGT1A6 2) polymorphisms in Caucasians and Asians relationships to serum bilimbin concentrations. Pharmacogenetics 1999 9 341-349. [Pg.307]

Three Japanese patients with Crigler-Naj-jar syndrome type I carry an identical nonsense mutation in the gene for UDP-glucuronosyltransferase. Jpn J Hum Genet 1995 40 253-257. [Pg.307]

Maruo Y, Sato H, Yamano T et al. Gilbert syndrome caused by a homozygous missense mutation (Tyr486Asp) of bilirubin UDP-glucuronosyltransferase gene. [Pg.307]

Walle UK and Walle T. 2002. Induction of human UDP-glucuronosyltransferase UGT1A1 by flavonoids-structural requirements. Drug Metab Dispos 30(5) 564-569. [Pg.175]

Obermayer-Straub, P., Strassburg, C.R, and Manns, M.R, Target proteins in human autoimmunity cytochromes P450 and UDP-glucuronosyltransferases, Can. J. Gastroenterol., 14, 429, 2000. [Pg.62]

To understand the MOA by which the thyroid tumors are produced, the effect of pyrethrins on rat thyroid gland, thyroid hormone levels, and hepatic thyroxine UDP-glucuronosyltransferase activity was also investigated [128]. The treatment of male rats with 8,000 ppm pyrethrins, female rats with 3,000 and 8,000 ppm pyrethrins, and both sexes with phenobarbital resulted in increased thyroid gland... [Pg.100]

Sugatani J, Kojima H, Ueda A et al (2001) The phenobarbital response enhancer module in the human bilirubin UDP-glucuronosyltransferase UGT1A1 gene and regulation by the nuclear receptor CAR. Hepatology 33 1232-1238... [Pg.109]

Nishiyama T, Kobori T, Arai K, et al. Identification of human UDP-glucuronosyltransferase isoform(s) responsible for the C-glucuronidation of phenylbutazone. Arch Biochem Biophys 2006 454(l) 72-79. [Pg.143]

Tukey RH, Strassburg CP. Human UDP-glucuronosyltransferases metabolism, expression, and disease. Annu Rev Pharmacol Toxicol 2000 40 581-616. [Pg.143]

Tephly TR, Green MD. UDP-Glucuronosyltransferases. In Levy RH, Thummel KE, Trager WF, et al., eds. Metabolic Drug Interactions. Philadelphia, PA Lippincott, Williams Wilkins 2000. [Pg.144]

Williams, J.A., Hyland, R., Jones, B.C., Smith, D.A., Hurst, S., Goosen, T.C., Peterkin, V., Koup, J.R. and Ball, S.E. (2004) Drug-drug interactions for UDP-glucuronosyltransferase substrates a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metabolism and Disposition, 32 (11), 1201-1208. [Pg.232]

Miley, M.J., Zielinska, A.K., Keenan, J.E., Bratton, S.M., Pandya, A.R. andRedinbol, M.R. (2007) Crystal structure of the cofactor-binding domain of the human phase II drug-metabolism enzyme UDP-glucuronosyltransferase 2B7. Journal of Molecular Biology,... [Pg.290]

Innocenti, F., Iyer, L., Ramirez, J., Green, M.D. and Ratain, M.J. (2001) Epirubicin glucuronidation is catalyzed by human UDP-glucuronosyltransferase 2B7. Drug Metabolism and Disposition, 29, 686-692. [Pg.291]

Radominska-Pandya, A., Czernik, P.J., Little, J.M., Battaglia, E. and Mackenzie, P.I. (1999) Structural and functional studies of UDP-glucuronosyltransferases. Drug Metabolism, Reviews, 31, 817-899. [Pg.312]

Chen, C., Staudinger, J.L. and Klaassen, C.D. (2003) Nuclear receptor, pregnane X receptor, is required for induction of UDP-glucuronosyltransferases in mouse liver by pregnenolone-16 alpha-carbonitrile. Drug Metabolism and Disposition, 31, 908—915. [Pg.312]

Yueh, M.F., Huang, Y.H., Hiller, A., Chen, S., Nguyen, N. and Tukey, R.H. (2003) Involvement of the xenobiotic response element (XRE) in Ah receptor-mediated induction of human UDP-glucuronosyltransferase 1A1. Journal of Biological Chemistry, 278, 15001-15006. [Pg.316]

Emi, Y., Ikushiro, S. and Iyanagi, T. (1996) Xenobiotic responsive element-mediated transcriptional activation in the UDP-glucuronosyltransferase family 1 gene complex. Journal of Biological Chemistry, 271, 3952-3958. [Pg.316]

Munzel, P.A., Lehmkoster, T., Bruck, M., Ritter, J.K. and Bock, K.W. (1998) Aryl hydrocarbon receptor-inducible or constitutive expression of human UDP glucuronosyltransferase UGT1A6. Archives of Biochemistry and Biophysics, 350, 72-78. [Pg.316]


See other pages where UDP-glucuronosyltransferase is mentioned: [Pg.923]    [Pg.194]    [Pg.70]    [Pg.425]    [Pg.426]    [Pg.116]    [Pg.283]    [Pg.320]    [Pg.269]    [Pg.101]    [Pg.296]    [Pg.312]    [Pg.322]   
See also in sourсe #XX -- [ Pg.194 ]

See also in sourсe #XX -- [ Pg.562 ]

See also in sourсe #XX -- [ Pg.164 ]

See also in sourсe #XX -- [ Pg.304 ]

See also in sourсe #XX -- [ Pg.170 ]

See also in sourсe #XX -- [ Pg.137 , Pg.144 ]

See also in sourсe #XX -- [ Pg.394 ]

See also in sourсe #XX -- [ Pg.629 ]

See also in sourсe #XX -- [ Pg.105 , Pg.110 ]




SEARCH



Glucuronosyltransferase

Glucuronosyltransferases

UDP

UDP-Glucuronosyltransferase (UGT)

UDP-glucuronosyltransferase enzymes

UDP-glucuronosyltransferases

UDP-glucuronosyltransferases

UDP-glucuronosyltransferases enzymes

© 2024 chempedia.info